Research programme: nuclear receptor inhibitors - Almirall and NuevolutionAlternative Names: RORγt inhibitor; RORγt inverse agonist
Latest Information Update: 04 Jan 2017
At a glance
- Originator Nuevolution
- Developer Almirall S.A.; Nuevolution
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Psoriatic arthritis; Rheumatoid arthritis